New Alport Patient Registry Now Enrolling
All Alport patients residing in the U.S. are encouraged to enroll today.
re: FDA Decision on Bardoxolone Methyl
February 25, 2022 On February 25th, the U.S. Food and Drug Administration (FDA) announced its decision not to approve a New Drug Application for the use of bardoxolone methyl as a treatment for Alport syndrome. Bardoxolone methyl was investigated for safety and efficacy in Alport patients through the CARDINAL Study, the first-ever clinical trial […]
Patient Guide: By Patients for Patients
December 13, 2024 Since the initial release of our Patient Guide in late 2021, we have seen many changes to the Alport syndrome landscape. Therefore, with the input of members of our Medical Advisory Committee, Emerging Leadership Council, and patients, we are proud to release our updated Patient Guide: By Patients for Patients. This […]